In line with this, the inhibition of TRPC6 with its specific blocker SKF-96365 or with siRNA reverted doxorubicin-induced epithelial-mesenchymal transition, hypoxia-induced Hif1- α expression and inhibit DNA damage, thereby attenuating drug resistance in hepatocellular carcinoma cells [113]. The gene discussed is TRPC6; the disease is hepatocellular carcinoma.